Close Menu

NEW YORK – Colposcopies and cervical biopsies can be intimidating, as well as painful and costly, but are often the best way for detecting cervical cancer or precancerous cervical lesions because less invasive diagnostic methods aren't as accurate or predictive. 

But researchers in France have developed a sequencing-based test that detects transcription levels of certain genes in high-risk human papillomavirus subtypes, and preliminary evaluations suggest it might someday serve as a surrogate for pathology and reduce unnecessary testing.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.